SCHEMBL3089990

SCHEMBL3089990

NC(=O)c1ccc(-c2ccccn2)cc1C1=CCCCC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.53
CHEK2 O96017 2/20 0.45
GRM2 Q14416 1/20 0.42
BTK Q06187 1/20 0.41
GRM5 P41594 2/20 0.40
DHODH Q02127 2/20 0.40
PARP1 P09874 1/20 0.40
PARP2 Q9UGN5 1/20 0.40
ACMSD Q8TDX5 1/20 0.39
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
KDM4E B2RXH2 1/20 0.38
PTGS2 P35354 1/20 0.38
SYK P43405 2/20 0.37
CAPN1 P07384 1/20 0.37
TGFBR1 P36897 1/20 0.37
SQOR Q9Y6N5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3089993 0.82 CSF1R (0.50) CSF1RCHEK2GRM5TDP1PTGS2
SCHEMBL3083131 0.81 CHUK (0.52) CSF1RCHEK2GRM2ACMSD
SCHEMBL3083329 0.79 MKNK1 (0.58) CSF1RCHEK2
SCHEMBL3086556 0.78 CSF1R (0.55) CSF1RGRM2DHODHPARP1ACMSD
SCHEMBL3910409 0.76 ACMSD (0.41) CSF1RGRM2BTKACMSDPTGS2
SCHEMBL3917188 0.75 ACMSD (0.40) CSF1RGRM2ACMSD
SCHEMBL5801711 0.75 CHEK2 (0.53) CHEK2BTKGRM5DHODHPARP1
SCHEMBL5189366 0.75 BCAT2 (0.49) CSF1RGRM2PARP1ACMSDMAPK1
SCHEMBL3076858 0.74 CSF1R (0.48) CSF1RGRM2ACMSD
SCHEMBL3081416 0.74 ACMSD (0.38) CSF1RGRM2ACMSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US claimed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP claimed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO claimed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER CSF1R 111/4885CHEK2 168/4885GRM2 1989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.